Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis B | 6 | 2024 | 711 | 2.930 |
Why?
|
Measles | 6 | 2022 | 180 | 2.820 |
Why?
|
HIV Infections | 44 | 2024 | 17569 | 2.800 |
Why?
|
Measles-Mumps-Rubella Vaccine | 5 | 2022 | 71 | 2.070 |
Why?
|
Rubella | 3 | 2022 | 55 | 2.010 |
Why?
|
Hepatitis B, Chronic | 4 | 2024 | 413 | 1.970 |
Why?
|
Mumps | 3 | 2022 | 71 | 1.940 |
Why?
|
Travel | 6 | 2024 | 805 | 1.530 |
Why?
|
Cost-Benefit Analysis | 22 | 2024 | 5536 | 1.210 |
Why?
|
HIV Integrase Inhibitors | 2 | 2020 | 165 | 1.090 |
Why?
|
Anti-Retroviral Agents | 7 | 2024 | 1789 | 1.080 |
Why?
|
Hepatitis B virus | 6 | 2024 | 533 | 0.800 |
Why?
|
Quarantine | 1 | 2024 | 186 | 0.780 |
Why?
|
Drug Resistance, Viral | 3 | 2020 | 869 | 0.770 |
Why?
|
CD4 Lymphocyte Count | 4 | 2017 | 2596 | 0.760 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2023 | 297 | 0.720 |
Why?
|
Vaccination | 5 | 2023 | 3437 | 0.710 |
Why?
|
Patient Isolation | 1 | 2020 | 101 | 0.670 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2023 | 238 | 0.650 |
Why?
|
Sarcoma, Kaposi | 1 | 2022 | 376 | 0.640 |
Why?
|
Rheumatic Diseases | 3 | 2021 | 659 | 0.640 |
Why?
|
Substance Abuse, Intravenous | 1 | 2023 | 530 | 0.620 |
Why?
|
Point-of-Care Systems | 3 | 2017 | 1238 | 0.620 |
Why?
|
Policy | 1 | 2022 | 513 | 0.610 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 212 | 0.610 |
Why?
|
Life Expectancy | 6 | 2024 | 1248 | 0.600 |
Why?
|
South Africa | 11 | 2024 | 1873 | 0.510 |
Why?
|
Exanthema | 4 | 2018 | 503 | 0.500 |
Why?
|
Anti-Bacterial Agents | 8 | 2021 | 7477 | 0.500 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2022 | 2204 | 0.500 |
Why?
|
Anti-HIV Agents | 7 | 2024 | 4573 | 0.480 |
Why?
|
Homosexuality, Male | 7 | 2024 | 1344 | 0.480 |
Why?
|
Communicable Disease Control | 4 | 2024 | 857 | 0.480 |
Why?
|
beta-Lactamases | 3 | 2006 | 307 | 0.480 |
Why?
|
Hepatitis C | 1 | 2024 | 1595 | 0.450 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2010 | 591 | 0.440 |
Why?
|
Smoking Cessation | 5 | 2024 | 2085 | 0.420 |
Why?
|
Viral Load | 2 | 2024 | 3396 | 0.420 |
Why?
|
Hepatitis B e Antigens | 2 | 2024 | 135 | 0.420 |
Why?
|
Outpatients | 1 | 2021 | 1600 | 0.410 |
Why?
|
United States | 30 | 2024 | 73039 | 0.410 |
Why?
|
Klebsiella Infections | 4 | 2007 | 146 | 0.400 |
Why?
|
Humans | 90 | 2024 | 768166 | 0.380 |
Why?
|
Enterobacteriaceae | 2 | 2010 | 161 | 0.380 |
Why?
|
Drug Monitoring | 1 | 2017 | 964 | 0.370 |
Why?
|
Adrenal Insufficiency | 1 | 2013 | 195 | 0.370 |
Why?
|
Health Resources | 2 | 2014 | 950 | 0.370 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2333 | 0.370 |
Why?
|
Dementia | 2 | 2024 | 2740 | 0.370 |
Why?
|
HIV Protease Inhibitors | 1 | 2013 | 430 | 0.370 |
Why?
|
Arthralgia | 1 | 2015 | 459 | 0.370 |
Why?
|
Oseltamivir | 1 | 2011 | 76 | 0.360 |
Why?
|
Adrenal Glands | 1 | 2013 | 557 | 0.360 |
Why?
|
Pituitary Gland | 1 | 2013 | 634 | 0.350 |
Why?
|
Escherichia coli Infections | 4 | 2007 | 524 | 0.330 |
Why?
|
Antiviral Agents | 3 | 2024 | 3073 | 0.330 |
Why?
|
Klebsiella | 2 | 2007 | 49 | 0.320 |
Why?
|
beta-Lactams | 1 | 2010 | 158 | 0.320 |
Why?
|
Enterobacteriaceae Infections | 1 | 2010 | 190 | 0.310 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3415 | 0.310 |
Why?
|
Hypothalamus | 1 | 2013 | 1004 | 0.300 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4362 | 0.290 |
Why?
|
Male | 43 | 2024 | 364719 | 0.280 |
Why?
|
Computer Simulation | 9 | 2024 | 6283 | 0.280 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 452 | 0.280 |
Why?
|
Adult | 36 | 2024 | 223646 | 0.270 |
Why?
|
beta-Lactam Resistance | 1 | 2007 | 79 | 0.270 |
Why?
|
Influenza, Human | 2 | 2023 | 1541 | 0.270 |
Why?
|
Mozambique | 2 | 2017 | 55 | 0.260 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 951 | 0.260 |
Why?
|
Female | 45 | 2024 | 397192 | 0.260 |
Why?
|
DNA, Viral | 2 | 2024 | 2204 | 0.260 |
Why?
|
Hypertension | 3 | 2024 | 8616 | 0.260 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3238 | 0.260 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1798 | 0.250 |
Why?
|
Klebsiella oxytoca | 1 | 2005 | 7 | 0.250 |
Why?
|
Dyslipidemias | 2 | 2024 | 873 | 0.250 |
Why?
|
Fluoroquinolones | 1 | 2007 | 309 | 0.250 |
Why?
|
Hepatitis B Surface Antigens | 2 | 2024 | 294 | 0.250 |
Why?
|
Mass Screening | 6 | 2024 | 5458 | 0.240 |
Why?
|
Refusal to Participate | 1 | 2024 | 30 | 0.240 |
Why?
|
HIV | 2 | 2023 | 1597 | 0.230 |
Why?
|
Health Care Costs | 7 | 2022 | 3239 | 0.230 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1886 | 0.230 |
Why?
|
Dideoxynucleosides | 1 | 2024 | 135 | 0.230 |
Why?
|
South Carolina | 1 | 2024 | 113 | 0.230 |
Why?
|
Cross Infection | 2 | 2010 | 1426 | 0.220 |
Why?
|
Drug Resistance, Bacterial | 2 | 2010 | 1063 | 0.220 |
Why?
|
Klebsiella pneumoniae | 1 | 2005 | 253 | 0.210 |
Why?
|
Lamivudine | 1 | 2024 | 367 | 0.210 |
Why?
|
Oxazines | 1 | 2024 | 358 | 0.200 |
Why?
|
Quality-Adjusted Life Years | 3 | 2024 | 1741 | 0.200 |
Why?
|
Depressive Disorder | 1 | 2015 | 3721 | 0.200 |
Why?
|
Piperidines | 2 | 2021 | 1667 | 0.200 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 2043 | 0.200 |
Why?
|
Middle Aged | 26 | 2024 | 223492 | 0.200 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 296 | 0.200 |
Why?
|
Atherosclerosis | 1 | 2017 | 3433 | 0.190 |
Why?
|
Tuberculosis | 1 | 2014 | 2029 | 0.190 |
Why?
|
Azathioprine | 1 | 2023 | 354 | 0.190 |
Why?
|
Drug Utilization | 1 | 2007 | 1189 | 0.190 |
Why?
|
Bleomycin | 1 | 2022 | 492 | 0.190 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2021 | 340 | 0.190 |
Why?
|
Anthozoa | 1 | 2021 | 65 | 0.180 |
Why?
|
Young Adult | 14 | 2024 | 60066 | 0.180 |
Why?
|
Etoposide | 1 | 2022 | 639 | 0.180 |
Why?
|
Age Distribution | 2 | 2023 | 2873 | 0.170 |
Why?
|
HIV-1 | 1 | 2017 | 6961 | 0.170 |
Why?
|
Vincristine | 1 | 2022 | 1040 | 0.170 |
Why?
|
Pseudomonas aeruginosa | 1 | 2007 | 1276 | 0.170 |
Why?
|
Kenya | 1 | 2022 | 757 | 0.170 |
Why?
|
Medicare Part D | 1 | 2024 | 355 | 0.160 |
Why?
|
Models, Theoretical | 2 | 2024 | 3573 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 819 | 0.160 |
Why?
|
Cross-Sectional Studies | 4 | 2021 | 26379 | 0.160 |
Why?
|
Diabetes Mellitus | 3 | 2024 | 5889 | 0.160 |
Why?
|
Immunization, Secondary | 1 | 2021 | 373 | 0.160 |
Why?
|
Nutrition Surveys | 2 | 2023 | 1738 | 0.160 |
Why?
|
Aged | 19 | 2024 | 171504 | 0.160 |
Why?
|
Tuberculosis, Cutaneous | 1 | 2018 | 17 | 0.160 |
Why?
|
Africa South of the Sahara | 2 | 2021 | 752 | 0.160 |
Why?
|
Pyrimidines | 2 | 2021 | 3048 | 0.150 |
Why?
|
Boston | 3 | 2020 | 9374 | 0.150 |
Why?
|
Infant Care | 1 | 2019 | 182 | 0.150 |
Why?
|
Serologic Tests | 1 | 2020 | 382 | 0.150 |
Why?
|
Mycobacterium Infections | 1 | 2018 | 122 | 0.150 |
Why?
|
Virology | 1 | 2017 | 76 | 0.140 |
Why?
|
Encephalitis, Tick-Borne | 1 | 2018 | 45 | 0.140 |
Why?
|
Phylogeny | 3 | 2018 | 2843 | 0.140 |
Why?
|
Encephalitis Viruses, Tick-Borne | 1 | 2018 | 48 | 0.140 |
Why?
|
Molecular Typing | 1 | 2017 | 115 | 0.140 |
Why?
|
Postnatal Care | 1 | 2019 | 273 | 0.140 |
Why?
|
Leptospirosis | 1 | 2017 | 45 | 0.140 |
Why?
|
Remission Induction | 1 | 2023 | 2410 | 0.140 |
Why?
|
Internal Medicine | 1 | 2024 | 1064 | 0.140 |
Why?
|
Mycobacterium | 1 | 2018 | 252 | 0.140 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2020 | 620 | 0.140 |
Why?
|
Escherichia coli | 2 | 2007 | 4214 | 0.130 |
Why?
|
Retrospective Studies | 9 | 2024 | 81762 | 0.130 |
Why?
|
Urban Population | 2 | 2017 | 2046 | 0.130 |
Why?
|
Radiography, Thoracic | 2 | 2020 | 1321 | 0.130 |
Why?
|
Depression | 2 | 2023 | 8230 | 0.130 |
Why?
|
Influenza Vaccines | 1 | 2023 | 781 | 0.130 |
Why?
|
Observation | 1 | 2017 | 310 | 0.130 |
Why?
|
Canada | 1 | 2021 | 2130 | 0.130 |
Why?
|
Housing | 1 | 2020 | 683 | 0.130 |
Why?
|
Budgets | 1 | 2017 | 232 | 0.130 |
Why?
|
Illness Behavior | 1 | 2015 | 23 | 0.120 |
Why?
|
Europe | 1 | 2022 | 3436 | 0.120 |
Why?
|
Universities | 1 | 2020 | 1005 | 0.120 |
Why?
|
Cohort Studies | 6 | 2022 | 41754 | 0.120 |
Why?
|
Prevalence | 6 | 2024 | 15869 | 0.120 |
Why?
|
Paclitaxel | 1 | 2022 | 1733 | 0.120 |
Why?
|
Epidemics | 1 | 2020 | 517 | 0.120 |
Why?
|
Aging | 3 | 2024 | 8744 | 0.120 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2020 | 1903 | 0.120 |
Why?
|
Tenosynovitis | 1 | 2014 | 57 | 0.120 |
Why?
|
Internationality | 1 | 2020 | 1008 | 0.110 |
Why?
|
Metagenomics | 1 | 2018 | 474 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2554 | 0.110 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12077 | 0.110 |
Why?
|
Amenorrhea | 3 | 2003 | 484 | 0.110 |
Why?
|
Treatment Refusal | 1 | 2017 | 433 | 0.110 |
Why?
|
Health Policy | 2 | 2024 | 2698 | 0.110 |
Why?
|
Ulcer | 1 | 2015 | 203 | 0.110 |
Why?
|
Fever | 3 | 2017 | 1614 | 0.110 |
Why?
|
Incidence | 5 | 2024 | 21538 | 0.110 |
Why?
|
Liver Cirrhosis | 1 | 2024 | 1960 | 0.110 |
Why?
|
Research Design | 2 | 2020 | 6211 | 0.110 |
Why?
|
Aged, 80 and over | 8 | 2024 | 59629 | 0.110 |
Why?
|
Refugees | 1 | 2021 | 615 | 0.100 |
Why?
|
Mobile Health Units | 1 | 2014 | 93 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2021 | 874 | 0.100 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13586 | 0.100 |
Why?
|
Treatment Outcome | 5 | 2019 | 65371 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3115 | 0.100 |
Why?
|
Pregnancy | 4 | 2024 | 30256 | 0.100 |
Why?
|
Infant | 4 | 2022 | 36535 | 0.100 |
Why?
|
Dengue | 1 | 2015 | 258 | 0.100 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15662 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2138 | 0.100 |
Why?
|
Dancing | 2 | 2003 | 105 | 0.100 |
Why?
|
Adolescent | 8 | 2024 | 89169 | 0.090 |
Why?
|
Lung | 3 | 2020 | 10099 | 0.090 |
Why?
|
Stroke | 2 | 2024 | 9755 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 2 | 2014 | 789 | 0.090 |
Why?
|
Child | 7 | 2024 | 80917 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1436 | 0.090 |
Why?
|
Hospitalization | 2 | 2020 | 10840 | 0.090 |
Why?
|
Risk Factors | 8 | 2024 | 74944 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2784 | 0.080 |
Why?
|
Child, Preschool | 3 | 2022 | 42669 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2024 | 2298 | 0.080 |
Why?
|
Equipment Contamination | 1 | 2010 | 183 | 0.080 |
Why?
|
Bone Diseases, Metabolic | 2 | 2003 | 411 | 0.080 |
Why?
|
Medicare | 2 | 2024 | 6809 | 0.080 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3216 | 0.080 |
Why?
|
Diagnosis, Differential | 4 | 2018 | 13014 | 0.080 |
Why?
|
Postoperative Complications | 1 | 2011 | 15832 | 0.080 |
Why?
|
Cost Savings | 1 | 2013 | 904 | 0.080 |
Why?
|
Exercise | 2 | 2021 | 5955 | 0.080 |
Why?
|
Morbidity | 1 | 2013 | 1755 | 0.070 |
Why?
|
Tongue Diseases | 1 | 2008 | 69 | 0.070 |
Why?
|
Oxazolidinones | 1 | 2008 | 98 | 0.070 |
Why?
|
Disease Outbreaks | 1 | 2017 | 1761 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2679 | 0.070 |
Why?
|
Smoking | 3 | 2020 | 9092 | 0.070 |
Why?
|
Rural Population | 1 | 2017 | 2325 | 0.070 |
Why?
|
Acetamides | 1 | 2008 | 259 | 0.070 |
Why?
|
Telemedicine | 1 | 2024 | 3109 | 0.070 |
Why?
|
Ceftazidime | 1 | 2006 | 57 | 0.070 |
Why?
|
Risk | 1 | 2017 | 9613 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 2011 | 863 | 0.060 |
Why?
|
Genotype | 1 | 2020 | 13045 | 0.060 |
Why?
|
Dideoxyadenosine | 1 | 2024 | 9 | 0.060 |
Why?
|
Ceftriaxone | 1 | 2006 | 175 | 0.060 |
Why?
|
Tennessee | 1 | 2024 | 123 | 0.060 |
Why?
|
Diet | 2 | 2021 | 8089 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2017 | 3620 | 0.060 |
Why?
|
Internship and Residency | 1 | 2024 | 5953 | 0.060 |
Why?
|
Microbial Sensitivity Tests | 1 | 2010 | 1967 | 0.060 |
Why?
|
Alkynes | 1 | 2024 | 326 | 0.060 |
Why?
|
Progesterone Congeners | 1 | 2003 | 43 | 0.060 |
Why?
|
Prospective Studies | 2 | 2019 | 54926 | 0.050 |
Why?
|
Blood Pressure | 1 | 2019 | 8543 | 0.050 |
Why?
|
Cyclopropanes | 1 | 2024 | 436 | 0.050 |
Why?
|
Benzoxazines | 1 | 2024 | 320 | 0.050 |
Why?
|
Population Density | 1 | 2023 | 193 | 0.050 |
Why?
|
Pseudomonas Infections | 1 | 2007 | 623 | 0.050 |
Why?
|
Condoms | 1 | 2024 | 337 | 0.050 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2003 | 155 | 0.050 |
Why?
|
Obesity | 2 | 2022 | 13090 | 0.050 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2018 | 1049 | 0.050 |
Why?
|
Knowledge | 1 | 2024 | 178 | 0.050 |
Why?
|
Immunization Schedule | 1 | 2023 | 228 | 0.050 |
Why?
|
Mental Disorders | 1 | 2022 | 6874 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2003 | 277 | 0.050 |
Why?
|
Developing Countries | 1 | 2014 | 2910 | 0.050 |
Why?
|
DNA, Bacterial | 2 | 2018 | 1478 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11519 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 198 | 0.050 |
Why?
|
Anti-Infective Agents | 1 | 2008 | 983 | 0.040 |
Why?
|
Risk Assessment | 1 | 2022 | 24315 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7454 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2010 | 22291 | 0.040 |
Why?
|
Harm Reduction | 1 | 2021 | 143 | 0.040 |
Why?
|
Hepatitis B Vaccines | 1 | 2021 | 178 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2005 | 4860 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9669 | 0.040 |
Why?
|
Treatment Failure | 1 | 2005 | 2661 | 0.040 |
Why?
|
Botswana | 1 | 2022 | 1058 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 404 | 0.040 |
Why?
|
Mycolic Acids | 1 | 2018 | 54 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2024 | 1259 | 0.040 |
Why?
|
Rickettsia | 1 | 2018 | 11 | 0.040 |
Why?
|
Hemorrhagic Fevers, Viral | 1 | 2018 | 23 | 0.040 |
Why?
|
Drug Combinations | 1 | 2024 | 2089 | 0.040 |
Why?
|
Base Composition | 1 | 2018 | 291 | 0.040 |
Why?
|
Masks | 1 | 2020 | 214 | 0.040 |
Why?
|
Heart Failure | 1 | 2022 | 11879 | 0.040 |
Why?
|
Hypothalamic Diseases | 1 | 1999 | 134 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2018 | 263 | 0.040 |
Why?
|
Cote d'Ivoire | 1 | 2017 | 65 | 0.040 |
Why?
|
Infectious Disease Incubation Period | 1 | 2017 | 16 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2020 | 963 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 819 | 0.040 |
Why?
|
Seasons | 1 | 2023 | 1524 | 0.040 |
Why?
|
Indonesia | 1 | 2017 | 131 | 0.040 |
Why?
|
Hospitals | 1 | 2010 | 3886 | 0.030 |
Why?
|
Drugs, Generic | 1 | 2022 | 455 | 0.030 |
Why?
|
Radiography | 2 | 2020 | 6983 | 0.030 |
Why?
|
Italy | 1 | 2018 | 856 | 0.030 |
Why?
|
Patient Care | 1 | 2022 | 629 | 0.030 |
Why?
|
Pandemics | 3 | 2020 | 8748 | 0.030 |
Why?
|
Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 2011 | 4262 | 0.030 |
Why?
|
Social Class | 1 | 2024 | 2008 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4786 | 0.030 |
Why?
|
Hyponatremia | 1 | 2018 | 279 | 0.030 |
Why?
|
Nicotine | 1 | 2020 | 680 | 0.030 |
Why?
|
Papillomavirus Vaccines | 1 | 2021 | 497 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22371 | 0.030 |
Why?
|
Time Factors | 2 | 2007 | 40218 | 0.030 |
Why?
|
Health Surveys | 1 | 2024 | 4057 | 0.030 |
Why?
|
Uveitis | 1 | 2018 | 398 | 0.030 |
Why?
|
Tick-Borne Diseases | 1 | 2014 | 37 | 0.030 |
Why?
|
Health Care Rationing | 1 | 2017 | 435 | 0.030 |
Why?
|
Genome, Viral | 1 | 2018 | 674 | 0.030 |
Why?
|
Vasculitis | 1 | 2018 | 525 | 0.030 |
Why?
|
Pancytopenia | 1 | 2014 | 102 | 0.030 |
Why?
|
Drug Costs | 1 | 2021 | 1195 | 0.030 |
Why?
|
DNA, Ribosomal | 1 | 2014 | 300 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 667 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2720 | 0.030 |
Why?
|
Nucleic Acid Hybridization | 1 | 2014 | 1305 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2014 | 526 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2024 | 1885 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2359 | 0.030 |
Why?
|
Models, Biological | 2 | 2020 | 9495 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2018 | 1479 | 0.020 |
Why?
|
Disease Transmission, Infectious | 1 | 2017 | 560 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2020 | 2008 | 0.020 |
Why?
|
Health Expenditures | 1 | 2022 | 2389 | 0.020 |
Why?
|
Headache | 1 | 2017 | 1263 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4055 | 0.020 |
Why?
|
Comorbidity | 1 | 2024 | 10590 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2018 | 1596 | 0.020 |
Why?
|
Virus Diseases | 1 | 2014 | 724 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8509 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2014 | 2732 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 2018 | 1930 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2014 | 1281 | 0.020 |
Why?
|
Color | 1 | 2008 | 296 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3721 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3239 | 0.020 |
Why?
|
Mortality | 1 | 2017 | 2911 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6793 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2210 | 0.020 |
Why?
|
Population Groups | 1 | 2006 | 209 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14729 | 0.010 |
Why?
|
Skin | 1 | 2018 | 4503 | 0.010 |
Why?
|
Bone Density | 3 | 2003 | 3573 | 0.010 |
Why?
|
Proteins | 1 | 1999 | 6009 | 0.010 |
Why?
|
Reference Values | 2 | 2002 | 4938 | 0.010 |
Why?
|
Models, Statistical | 1 | 2017 | 5107 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15948 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 17622 | 0.010 |
Why?
|
Puberty, Delayed | 1 | 2002 | 124 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10101 | 0.010 |
Why?
|
Menarche | 1 | 2003 | 538 | 0.010 |
Why?
|
Wrist Joint | 1 | 2002 | 267 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26422 | 0.010 |
Why?
|
Fractures, Stress | 1 | 2002 | 205 | 0.010 |
Why?
|
Logistic Models | 1 | 2014 | 13290 | 0.010 |
Why?
|
Longitudinal Studies | 2 | 2003 | 14783 | 0.010 |
Why?
|
Thyroid Hormones | 1 | 1999 | 407 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 13490 | 0.010 |
Why?
|
Spine | 1 | 2002 | 1140 | 0.010 |
Why?
|
Estradiol | 1 | 2002 | 1951 | 0.010 |
Why?
|
Testosterone | 1 | 2002 | 2491 | 0.010 |
Why?
|
Leptin | 1 | 1999 | 1599 | 0.010 |
Why?
|
Animals | 1 | 2021 | 169246 | 0.010 |
Why?
|
Chronic Disease | 1 | 2002 | 9384 | 0.000 |
Why?
|